Vis enkel innførsel

dc.contributor.authorTollefsen, Knut Erik
dc.contributor.authorScholz, Stefan
dc.contributor.authorCronin, Mark T.
dc.contributor.authorEdwards, Stephen W.
dc.contributor.authorde Knecht, Joop
dc.contributor.authorCrofton, Kevin
dc.contributor.authorGarcia-Reyero, Natalia
dc.contributor.authorHartung, Thomas
dc.contributor.authorWorth, Andrew
dc.contributor.authorPatlewicz, Grace
dc.date.accessioned2018-10-05T08:08:19Z
dc.date.available2018-10-05T08:08:19Z
dc.date.created2016-05-05T14:57:22Z
dc.date.issued2014
dc.identifier.citationRegulatory toxicology and pharmacology. 2014, 70 (3), 629-640.nb_NO
dc.identifier.issn0273-2300
dc.identifier.urihttp://hdl.handle.net/11250/2566582
dc.description.abstractChemical regulation is challenged by the large number of chemicals requiring assessment for potential human health and environmental impacts. Current approaches are too resource intensive in terms of time, money and animal use to evaluate all chemicals under development or already on the market. The need for timely and robust decision making demands that regulatory toxicity testing becomes more cost-effective and efficient. One way to realize this goal is by being more strategic in directing testing resources; focusing on chemicals of highest concern, limiting testing to the most probable hazards, or targeting the most vulnerable species. Hypothesis driven Integrated Approaches to Testing and Assessment (IATA) have been proposed as practical solutions to such strategic testing. In parallel, the development of the Adverse Outcome Pathway (AOP) framework, which provides information on the causal links between a molecular initiating event (MIE), intermediate key events (KEs) and an adverse outcome (AO) of regulatory concern, offers the biological context to facilitate development of IATA for regulatory decision making. This manuscript summarizes discussions at the Workshop entitled “Advancing AOPs for Integrated Toxicology and Regulatory Applications” with particular focus on the role AOPs play in informing the development of IATA for different regulatory purposes.nb_NO
dc.language.isoengnb_NO
dc.publisherElseviernb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleApplying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA)nb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.rights.holder2014 Elsevier Inc. All rights reserved.nb_NO
dc.source.pagenumber629-640nb_NO
dc.source.volume70nb_NO
dc.source.journalRegulatory toxicology and pharmacologynb_NO
dc.source.issue3nb_NO
dc.identifier.doi10.1016/j.yrtph.2014.09.009
dc.identifier.cristin1354100
dc.relation.projectNorges forskningsråd: 221455nb_NO
cristin.unitcode7464,20,13,0
cristin.unitnameØkotoksikologi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal